GSK acted “after lying in wait, and abusing the patent system” to “siphon resources and earnings” for Moderna’s “lauded efforts to address a global pandemic,” according to Moderna’s answer and counterclaims filed Thursday in the US District Court for the District of Delaware.
GSK is trying to do “in the courtroom what it could not accomplish (and, in fact, failed to do) in the laboratory, ...